Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Early vs Late Phase Hetrombopag Olamine Formulations
NCT04688008Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hetrombopag in Thrombocytopenia, immune thrombocytopenia (ITP) and aplastic anemia (2 arms), sponsored by Hengrui. Primary endpoints: Peak Plasma Concentration, Area Under the Plasma Concentration vs Time Curve (0-120h) and 1 more. Started Sep 2020; status: completed.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopeniaimmune thrombocytopenia (ITP)aplastic anemia
Beyond the preview
Go deeper on NCT04688008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688008.